Back to Cell Types

OVMANAHomo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 16 publications

Quick Overview

OVMANA is a human ovarian cancer cell line derived from clear cell adenocarcinoma, used in cancer research for studying molecul...

Detailed Summary

OVMANA is a human ovarian cancer cell line established from a clear cell adenocarcinoma, commonly used in cancer research to investigate molecular mechanisms and therapeutic responses. It has been utilized in studies focusing on genetic alterations, such as mutations in the PIK3CA gene, and their implications in cancer progression. Research involving OVMANA has contributed to understanding the role of the PI3K/AKT/mTOR pathway in ovarian cancer, highlighting potential targets for therapeutic intervention. Additionally, OVMANA has been part of studies examining the effects of chemotherapy agents and their efficacy in different cancer subtypes, providing insights into treatment strategies. The cell line's characteristics make it a valuable tool for exploring the complexities of ovarian cancer biology and developing targeted therapies.

Research Applications

Genetic Alterations AnalysisDrug Response StudiesMolecular Mechanisms of Cancer ProgressionPI3K/AKT/mTOR Pathway Research

Key Characteristics

Derived from clear cell adenocarcinomaUsed in studies of PIK3CA mutationsPart of chemotherapy efficacy researchRelevant for understanding ovarian cancer biology

Generated on 6/19/2025

Basic Information

Database ID	CVCL_3111
Species	Homo sapiens (Human)
Tissue Source	Ovary[UBERON:UBERON_0000992]

Donor Information

Age	51
Age Category	Adult
Sex	Female
Race	asian

Disease Information

Disease	Clear cell adenocarcinoma of the ovary
Lineage	Ovary/Fallopian Tube
Subtype	Clear Cell Ovarian Cancer
OncoTree Code	CCOV

DepMap Information

Source Type	HSRRB
Source ID	ACH-000646_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	PIK3CA	p.Glu545Val (c.1634A>T)	Unspecified	-	PubMed=22705003

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12,13

D13S317

8,9

D16S539

10

D18S51

16

D19S433

14

D21S11

28,31

D2S1338

24

D3S1358

15

D5S818

13

D7S820

10,11

D8S1179

10,15

FGA

21,24

TH01

7,9

TPOX

8

vWA

15,16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

Data Brief 7:1302-1305(2016).

Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

J. Proteomics 139:77-83(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Type-specific cell line models for type-specific ovarian cancer research.

Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

PLoS ONE 8:E72162-E72162(2013).

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.

Miyazaki K.

Hum. Pathol. 43:2197-2206(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";

Anderson M.L., Matzuk M.M.

Mol. Endocrinol. 24:447-463(2010).

Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.

Hirohashi S., Inazawa J., Imoto I.

Cancer Res. 67:7095-7105(2007).

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Edwards P.A.W., Caldas C.

Carcinogenesis 26:923-930(2005).

Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.

Hirahara F., Shirotake S.

Cancer Lett. 162:39-48(2001).

Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.

Kitamura H., Minaguchi H.

Br. J. Cancer 76:829-835(1997).

Web Resources